The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Sage Therapeutics Inc. (SAGE) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $43.32. The Sage Therapeutics Inc. has recorded 35,119 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sage Therapeutics Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $43.32 and fluctuated between $44.39 as its day high and $42.58 as its day low. The current market capitalization of Sage Therapeutics Inc. is $2.82B. A total of 0.56 million shares were traded on the day, compared to an average of 505.48K shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, SAGE has seen 10 BUY and 5 SELL insider trades, representing the acquisition of 27,826 and the disposition of 6,567 shares. Over the last 12 months, there were 14 BUYs and 5 SELLs from insiders. Insiders purchased 81,275 shares during that period but sold 6,567.
In the most recent transaction, JONAS JEFFREY M sold 11,643 shares of SAGE for 44.61 per share on Feb 10. After the transaction, the Director now owns 121,981 company shares. In a previous transaction on Nov 10, Greene Barry E bought 14,500 shares at 34.48 per share. SAGE shares that President and CEO owns now total 46,940.
Among the insiders who bought shares, Golumbeski George acquired of 8,000 shares on May 05 at a per-share price of $31.45. This resulted in the Director holding 8,000 shares of SAGE after the transaction.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for SAGE in the last 3 months, the mean price target is $57.90 with high estimates of $105.00 and low estimates of $36.00. In terms of 52-week highs and lows, SAGE has a high of $49.56 and a low of $27.36.
As of this writing, SAGE has an earnings estimate of -$2.39 per share for the current quarter. EPS was calculated based on a consensus of 21 estimates, with a high estimate of -$2.01 per share and a lower estimate of -$2.68. The company reported an EPS of -$2.13 in the last quarter, which was 0.90% higher than expectations of -$2.15.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 23 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for SAGE is Sell with a score of 3.82. A total of 11 analysts rated the stock as Buy while 0 rated it as Overweight while 12 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.